5-year OPTIC data showed a single injection of Ixo-vec gene therapy cut annualized anti-VEGF injections 87%, with sustained aflibercept expression and no new safety signals, in a high-need population with nAMD.
Szilárd Kiss MD, FASRS
Advertisement
Szilárd Kiss, MD, FASRS, is professor of ophthalmology and professor of genetic medicine at Weill Cornell Medicine.
Articles by Szilárd Kiss MD, FASRS
Advertisement
Latest Updated Articles
Advertisement
Advertisement